[Prophylactic effects of mitomycin C (MMC) on the liver recurrence in a rabbit gastric VX2 cancer model with high frequency of the recurrence].
Prophylactic effects of mitomycin C (MMC) injection protocol with different dose, periods and routes on liver recurrence were examined, using 53 gastric VX2 cancer rabbits. All the gastric cancer lesions without liver metastases were resected 14 days after implantation of VX2 cancer cells into the stomach, and all the animals were autopsied 14 days after resection. Multiple liver recurrence was found in 75% of MMC non-injection control 8 rabbits. The recurrence was not found in 10 animals with portal MMC 0.5 and 0.25mg/kg injection after resection, although 80% of 5 animals with the 0.125mg/kg injection after resection revealed the recurrence. The recurrence was not found in 4 animals with peripheral MMC 1.0mg/kg injection, but found in 60% of 5 animals with the MMC 0.5mg/kg injection after resection. In the animals with peripheral MMC 0.25mg/kg injection 2, 1 and 0 days before resection and with portal MMC 0.125mg/mg injection after resection, the recurrence was found in 83, 60 and 80% of 6, 5 and 5 respective animals. These results suggest that prophylactic injection of MMC for liver recurrence is more effective in portal than peripheral injection, but that the preoperative and peripheral injection has no efficacy.
Tada
Y
Y
First Department of Surgery, Kobe University School of Medicine, Japan.
Tabuchi
Y
Y
Nakamura
T
T
Saitoh
Y
Y
D000818:Animals; D004195:Disease Models, Animal; D005260:Female; D007275:Injections, Intravenous; D008113:Liver Neoplasms / Q000473:pathology / Q000517:prevention & control / Q000556:secondary*; D016685:Mitomycin / Q000008:administration & dosage*; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D009368:Neoplasm Transplantation; D011169:Portal Vein; D011817:Rabbits; D013274:Stomach Neoplasms / Q000473:pathology*
D016685:Mitomycin